BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 21481332)

  • 1. [Intermittent treatment regimens and the rational (efficient) use of biologic agents in psoriasis].
    Moreno-Ramírez D
    Actas Dermosifiliogr; 2011 May; 102(4):241-3. PubMed ID: 21481332
    [No Abstract]   [Full Text] [Related]  

  • 2. New treatments for psoriasis: which biologic is best?
    Nelson AA; Pearce DJ; Fleischer AB; Balkrishnan R; Feldman SR
    J Dermatolog Treat; 2006; 17(2):96-107. PubMed ID: 16766334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching biologics for psoriasis.
    Ormerod AD
    Br J Dermatol; 2010 Oct; 163(4):667-9. PubMed ID: 20854399
    [No Abstract]   [Full Text] [Related]  

  • 4. Switching to adalimumab in patients with moderate to severe psoriasis who have failed on etanercept: a retrospective case cohort study.
    Woolf RT; Smith CH; Robertson K; Barker JN
    Br J Dermatol; 2010 Oct; 163(4):889-92. PubMed ID: 20854408
    [No Abstract]   [Full Text] [Related]  

  • 5. Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasis.
    Leman J; Burden AD
    Br J Dermatol; 2012 Nov; 167 Suppl 3():12-20. PubMed ID: 23082811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment period.
    Nelson AA; Pearce DJ; Fleischer AB; Balkrishnan R; Feldman SR
    J Am Acad Dermatol; 2008 Jan; 58(1):125-35. PubMed ID: 17996329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between the type and length of tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis.
    Wu JJ; Poon KY; Bebchuk JD
    J Drugs Dermatol; 2013 Aug; 12(8):899-903. PubMed ID: 23986163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Consecutive use of different biological therapies in the treatment of psoriasis.
    Costanzo A; Papoutsaki M; Mazzotta A; Chimenti S
    Br J Dermatol; 2007 Aug; 157(2):394. PubMed ID: 17553044
    [No Abstract]   [Full Text] [Related]  

  • 9. Switching between antitumour necrosis factor alpha biologic agents--is patient weight an important consideration?
    Downs AM
    Br J Dermatol; 2009 May; 160(5):1123-4. PubMed ID: 19292716
    [No Abstract]   [Full Text] [Related]  

  • 10. Adalimumab vs. etanercept in psoriasis.
    Downs AM
    Clin Exp Dermatol; 2007 Sep; 32(5):593. PubMed ID: 17692064
    [No Abstract]   [Full Text] [Related]  

  • 11. [Innovative therapeutic options for psoriatic arthritis: TNFalpha inhibitors].
    Lehnen M; Goos M; Dissemond J
    Dtsch Med Wochenschr; 2004 Mar; 129(12):634-8. PubMed ID: 15011134
    [No Abstract]   [Full Text] [Related]  

  • 12. The evolving role of biologics in the treatment of pediatric psoriasis.
    Luu M; Cordoro KM
    Skin Therapy Lett; 2013 Feb; 18(2):1-4. PubMed ID: 23508772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biologic therapy for psoriasis: the tumor necrosis factor inhibitors infliximab and etanercept.
    Weinberg JM; Saini R
    Cutis; 2003 Jan; 71(1):25-9. PubMed ID: 12553627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ustekinumab treats psoriasis refractory to seven conventional and biologic therapies.
    Rallis E; Verros CD
    Dermatol Online J; 2011 Apr; 17(4):14. PubMed ID: 21549089
    [No Abstract]   [Full Text] [Related]  

  • 15. Trial watch: novel biologic for psoriasis shows superiority over current best-seller.
    Nat Rev Drug Discov; 2008 Nov; 7(11):880-1. PubMed ID: 18974743
    [No Abstract]   [Full Text] [Related]  

  • 16. A scientific debate: key clinical questions in the management of psoriasis.
    Stingl G
    J Eur Acad Dermatol Venereol; 2012 Aug; 26 Suppl 5():1. PubMed ID: 22758910
    [No Abstract]   [Full Text] [Related]  

  • 17. Anti-TNF-alpha therapy in childhood pustular psoriasis.
    Pereira TM; Vieira AP; Fernandes JC; Antunes H; Basto AS
    Dermatology; 2006; 213(4):350-2. PubMed ID: 17135745
    [No Abstract]   [Full Text] [Related]  

  • 18. Economic evaluation of biologic therapies for the treatment of moderate to severe psoriasis in the United States.
    Anis AH; Bansback N; Sizto S; Gupta SR; Willian MK; Feldman SR
    J Dermatolog Treat; 2011 Apr; 22(2):65-74. PubMed ID: 20443663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eosinophilia during psoriasis treatment with TNF antagonists.
    Malisiewicz B; Murer C; Pachlopnik Schmid J; French LE; Schmid-Grendelmeier P; Navarini AA
    Dermatology; 2011; 223(4):311-5. PubMed ID: 22301393
    [No Abstract]   [Full Text] [Related]  

  • 20. Cost-efficacy of adalimumab, etanercept, infliximab and ustekinumab for moderate-to-severe plaque psoriasis.
    Ferrándiz C; García A; Blasco AJ; Lázaro P
    J Eur Acad Dermatol Venereol; 2012 Jun; 26(6):768-77. PubMed ID: 22126264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.